Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

Related

Vinge advises Fidelio Capital in the divestment of a minority stake in Odevo to CVC Capital Partners

Vinge has advised Fidelio Capital (“Fidelio”) and the other shareholders of Odevo Group (“Odevo”) in connection with the divestment of a minority shareholding to funds controlled by CVC Capital Partners (“CVC”). Fidelio, the existing management team and other minority shareholders of Odevo will retain a majority holding in the company.
August 28, 2024

Vinge advises evroc in financing round

Vinge has advised Swedish evroc, which is planning to construct several large data centres in Europe and become a leading supplier of cloud services, to raise approximately SEK 500 million. The financing round participants include, among others, the previous investors EQT Ventures and Norrsken VC as well as the new investor Blisce, a French private equity firm.
August 22, 2024

Vinge advises Lunar Bank on the sale of its Swedish consumer loan portfolio to Morrow Bank

Vinge has advised Lunar Bank A/S on the sale of its approximately SEK 1.6 billion consumer loan portfolio to Morrow Bank ASA.
August 20, 2024